Ilaris NIS in Korea

Study Summary

This is a study to evaluate safety and effectiveness of Ilaris in adult and pediatric patients receiving the drug in a clinical setting for any of the following indications, Hereditary Periodic Fever Syndromes, Cryopyrin-associated periodic syndromes (CAPS), colchicine resistance familial Mediterranean fever (crFMF), TNF receptor associated periodic syndrome (TRAPS), Hyper-IgD syndrome / Mevalonate kinase deficiency (HIDS/MKD) or Systemic juvenile idiopathic arthritis (sJIA).

Conditions

Hereditary Periodic Fever Syndromes Cryopyrin-associated Periodic Syndromes (CAPS)Colchicine Resistance Familial Mediterranean Fever (crFMF)TNF Receptor Associated Periodic Syndrome (TRAPS)Hyper-IgD Syndrome / Mevalonate Kinase Deficiency (HIDS/MKD)Systemic Juvenile Idiopathic Arthritis (sJIA)

Interventions / Drugs

Ilaris

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment25 participants

Primary Completion—

Lead SponsorNovartis Pharmaceuticals

Data Retrieved2026-04-11 02:55:49.152083+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.